Moreover, our results demonstrated that acetate supplementation alleviates DNCB-induced AD-like skin damage, which is related to the presence of the FFAR2 and the Th2 (Gata3) pathways, but not to FFAR3 and GRP109a. This evidence concerns the gene GATA3 and Alzheimer disease.